Imatinib in Acute Ischaemic Stroke

Summary

Imatinib in Acute Ischaemic Stroke is a clinical trial^[1].

Key Facts

• Imatinib in Acute Ischaemic Stroke is in the country of Sweden^[2].
• Imatinib in Acute Ischaemic Stroke's instance of is recorded as clinical trial^[3].
• Imatinib in Acute Ischaemic Stroke's start time is recorded as +2018-10-01T00:00:00Z^[4].
• Imatinib in Acute Ischaemic Stroke's end time is recorded as +2021-12-31T00:00:00Z^[5].
• Imatinib in Acute Ischaemic Stroke's main subject is recorded as stroke^[6].
• Imatinib in Acute Ischaemic Stroke's main subject is recorded as cerebral infarction^[7].
• Imatinib in Acute Ischaemic Stroke's main subject is recorded as ischemia^[8].
• Imatinib in Acute Ischaemic Stroke's number of participants is recorded as {'unit': '1', 'amount': '+1260'}^[9].
• Imatinib in Acute Ischaemic Stroke's title is recorded as Imatinib in Acute Ischaemic Stroke: A Phase 3, Randomized, Double-blind, Placebo Controlled, Parallel-arm Efficacy Trial of Imatinib in Acute Ischaemic Stroke^[10].
• Imatinib in Acute Ischaemic Stroke's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Imatinib in Acute Ischaemic Stroke's ClinicalTrials.gov ID is recorded as NCT03639922^[12].
• Imatinib in Acute Ischaemic Stroke's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+85'}^[13].
• Imatinib in Acute Ischaemic Stroke's research intervention is recorded as imatinib mesylate^[14].
• Imatinib in Acute Ischaemic Stroke's clinical trial phase is recorded as phase III clinical trial^[15].
• Imatinib in Acute Ischaemic Stroke's research site is recorded as University of Gothenburg^[16].
• Imatinib in Acute Ischaemic Stroke's research subject recruitment status is recorded as recruiting^[17].
• Imatinib in Acute Ischaemic Stroke's study type is recorded as interventional study^[18].